Industrial partners
IDT Biologika
Together with the company IDT Biologika, the DZIF is developing a vaccine against the MERS coronavirus in a consortium of scientists and clinicians. The company IDT Biologika developed its own cell line for the production of the vaccine on a larger scale. The company is also a partner and consortium leader in the ongoing clinical trial of the vaccine candidate MVA-SARS-2-ST.